兄弟科技(002562.SZ):兄弟維生素與大豐製藥合併完成 大豐製藥依法註銷登記
格隆匯1月16日丨兄弟科技(002562.SZ)公佈,公司於2019年11月22日召開了第四屆董事會第二十七次會議,審議通過了《關於全資子公司江蘇兄弟維生素有限公司與大豐兄弟製藥有限公司合併的議案》,擬將全資子公司江蘇兄弟維生素有限公司(“兄弟維生素”)與全資子公司大豐兄弟製藥有限公司(“大豐製藥”)實施合併,由全資子公司兄弟維生素為主體吸收合併大豐製藥。合併後,大豐製藥法人資格解散註銷。大豐製藥原有業務、債權債務全部由兄弟維生素承繼,現有員工隨業務全部轉入兄弟維生素。
近日,大豐製藥收到鹽城市大豐區行政審批局《公司准予註銷登記的通知書》,大豐製藥依法註銷登記。兄弟維生素完成了吸收合併的工商變更登記手續,並取得了鹽城市大豐區行政審批局頒發的《營業執照》。
此次合併,將整合公司資源,提高子公司的運行效率、提升業績和增強公司整體盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.